Sanofi and Regeneron's Dupilumab Named "Clinical Advance of the Year" by Scrip Intelligence

Sanofi and Regeneron's Dupilumab Named "Clinical Advance of the Year" by Scrip

PR Newswire

PARIS and TARRYTOWN, N.Y., Nov. 25, 2013

PARIS and TARRYTOWN, N.Y., Nov. 25, 2013 /PRNewswire/ --Sanofi (EURONEXT: SAN
and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today
announced that the Phase 2a study of dupilumab in asthma was named "Clinical
Advance of the Year" by Scrip Intelligence at the 9th annual Scrip Awards. The
award was announced last week by Scrip, a leading pharmaceutical industry

Dupilumab is a fully-human monoclonal antibody that is being developed by
Regeneron and Sanofi for the treatment of asthma, atopic dermatitis, and nasal

George D. Yancopoulos, M.D., Ph. D., Chief Scientific Officer of Regeneron and
President of Regeneron Laboratories, said, "We appreciate the recognition by
Scrip that dupilumab is one of the most exciting emerging clinical candidates
in the industry. We feel that this award is additional validation of the
overall depth and productivity of our R&D team and the powerful VelociSuite^®
technologies they employ, which have delivered dupilumab and several other
investigational therapeutic opportunities."

"On behalf of all of the men and women within our organizations working
diligently to develop this investigational treatment, we are truly honored by
this award," said Elias Zerhouni, M.D., President Global R&D, Sanofi. "The
ultimate recognition for their innovative research, at the end of the day, is
when we are able to deliver improved solutions to patients."

Award winners were selected by a 15-member panel of leading pharmaceutical
industry executives, consultants, and researchers. More information about the
panel is available at: In
2012, Scrip honored Regeneron as its Biotech Company of the Year.

About Dupilumab (REGN668/SAR231893)
Dupilumab is a fully human investigational monoclonal antibody delivered by
subcutaneous injection that targets the alpha subunit of the interleukin 4
receptor (IL-4R alpha). By blocking IL-4R alpha, dupilumab modulates
signaling of both IL-4 and IL-13, drivers of Th2 (Type 2 helper T cell) immune
response. Dupilumab was created using Regeneron's VelocImmune^® gene
modification technologies and is being co-developed with Sanofi. Dupilumab is
currently in Phase 2 studies in atopic dermatitis, asthma and nasal polyposis.

About Sanofi
Sanofi, an integrated global healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients' needs. Sanofi has core
strengths in the field of healthcare with seven growth platforms: diabetes
solutions, human vaccines, innovative drugs, consumer healthcare, emerging
markets, animal health and the new Genzyme. Sanofi is listed in Paris
(EURONEXT: SAN) and in New York (NYSE: SNY).

About Regeneron Pharmaceuticals, Inc.
Regeneron is a leading science-based biopharmaceutical company based in
Tarrytown, New York that discovers, invents, develops, manufactures, and
commercializes medicines for the treatment of serious medical conditions.
Regeneron markets medicines for eye diseases, colorectal cancer, and a rare
inflammatory condition and has product candidates in development in other
areas of high unmet medical need, including hypercholesterolemia, oncology,
rheumatoid arthritis, asthma, and atopic dermatitis. For additional
information about the company, please visit

Sanofi Forward-Looking Statements
This press release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, as amended. Forward-looking
statements are statements that are not historical facts. These statements
include projections and estimates and their underlying assumptions, statements
regarding plans, objectives, intentions and expectations with respect to
future financial results, events, operations, services, product development
and potential, and statements regarding future performance. Forward-looking
statements are generally identified by the words "expects", "anticipates",
"believes", "intends", "estimates", "plans" and similar expressions. Although
Sanofi's management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned that
forward-looking information and statements are subject to various risks and
uncertainties, many of which are difficult to predict and generally beyond the
control of Sanofi, that could cause actual results and developments to differ
materially from those expressed in, or implied or projected by, the
forward-looking information and statements. These risks and uncertainties
include among other things, the uncertainties inherent in research and
development, future clinical data and analysis, including post marketing,
decisions by regulatory authorities, such as the FDA or the EMA, regarding
whether and when to approve any drug, device or biological application that
may be filed for any such product candidates as well as their decisions
regarding labelling and other matters that could affect the availability or
commercial potential of such product candidates, the absence of guarantee that
the product candidates if approved will be commercially successful, the future
approval and commercial success of therapeutic alternatives, the Group's
ability to benefit from external growth opportunities, trends in exchange
rates and prevailing interest rates, the impact of cost containment policies
and subsequent changes thereto, the average number of shares outstanding as
well as those discussed or identified in the public filings with the SEC and
the AMF made by Sanofi, including those listed under "Risk Factors" and
"Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual
report on Form 20-F for the year ended December 31, 2012. Other than as
required by applicable law, Sanofi does not undertake any obligation to update
or revise any forward-looking information or statements.

Regeneron Forward-Looking Statements
This news release includes forward-looking statements that involve risks and
uncertainties relating to future events and the future performance of
Regeneron, and actual events or results may differ materially from these
forward-looking statements. Words such as "anticipate," "expect," "intend,"
"plan," "believe," "seek," "estimate," variations of such words, and similar
expressions are intended to identify such forward-looking statements, although
not all forward-looking statements contain these identifying words. These
statements concern, and these risks and uncertainties include, among others,
the nature, timing, and possible success and therapeutic applications of
Regeneron's products, product candidates, and research and clinical programs
now underway or planned, including without limitation dupilumab; unforeseen
safety issues resulting from the administration of products and product
candidates in patients, including serious complications or side effects in
connection with the use of Regeneron's product candidates in clinical trials;
the likelihood and timing of possible regulatory approval and commercial
launch of Regeneron's late-stage product candidates; ongoing regulatory
obligations and oversight impacting Regeneron's research and clinical programs
and business; determinations by regulatory and administrative governmental
authorities which may delay or restrict Regeneron's ability to continue to
develop or commercialize Regeneron's products and product candidates;
competing drugs and product candidates that may be superior to Regeneron's
products and product candidates; uncertainty of market acceptance and
commercial success of Regeneron's products and product candidates; the ability
of Regeneron to manufacture and manage supply chains for multiple products and
product candidates; coverage and reimbursement determinations by third-party
payers, including Medicare and Medicaid; unanticipated expenses; the costs of
developing, producing, and selling products; the ability of Regeneron to meet
any of its sales or other financial projections or guidance and changes to the
assumptions underlying those projections or guidance; the potential for any
license or collaboration agreement, including Regeneron's agreements with
Sanofi and Bayer HealthCare, to be cancelled or terminated without any further
product success; and risks associated with third party intellectual property
and pending or future litigation relating thereto. A more complete description
of these and other material risks can be found in Regeneron's filings with the
United States Securities and Exchange Commission, including its Form 10-K for
the year ended December 31, 2012 and its Form 10-Q for the quarterly period
ended September 30, 2013. The reader is cautioned not to rely on any
forward-looking statements made by Regeneron. Regeneron does not undertake any
obligation to update publicly any forward-looking statement, including without
limitation any financial projection or guidance, whether as a result of new
information, future events, or otherwise.

Sanofi Contacts:
Media Relations   Investor Relations
Jack Cox                                   Sebastien Martel
Tel.: + (33) 1 53 77 46 46                   Tel.: + (33) 1 53 77 45 45               
Regeneron Contacts:
Media Relations                Investor Relations
Peter Dworkin                   Manisha Narasimhan, Ph.D.
Tel: 1 (914) 847-7640                     Tel: 1 (914) 847-5126       

SOURCE Regeneron Pharmaceuticals, Inc.

Press spacebar to pause and continue. Press esc to stop.